Objective: Long-acting injectable (LAI) aripiprazole is recommended to be combined with oral aripiprazole for 2 weeks after its introduction. However, we often experience patients who require more than 2 weeks of combined use. Therefore, differences in combination periods need to be examined.
| INTRODUCTION
Long-acting injectable (LAI) antipsychotics (APs) are important pharmacotherapies for schizophrenia. In addition to higher adherence, LAI APs have various advantages such as reducing the burden of confirming medication compliance in patients, reducing gastrointestinal absorption issues, and reducing the risk of overdose (Hasan et al., 2013) . Although a randomized trial revealed no significant difference in efficacy or safety between LAI and oral APs (Kishimoto et al., 2014; Misawa, Kishimoto, Hagi, Kane, & Correll, 2016) , meta-analysis of mirror-image studies and clinical data showed that LAI APs are associated with reduced hospitalization frequency (Kishimoto, Nitta, Borenstein, Kane, & Correll, 2013; Tiihonen et al., 2017) .
Three types of second-generation AP LAIs (aripiprazole, risperidone, and paliperidone) have been approved for use in Japan, but the regimen for each is different. For example, paliperidone can be immediately switched to LAI, but aripiprazole and risperidone must be co-administered with an oral agent for a certain period.
The LAI aripiprazole regimen was simulated based on pharmacokinetic parameters, such as a steady-state serum concentration, and 400-mg LAI aripiprazole combined with oral aripiprazole for 2 weeks was equivalent to daily oral doses of 10-to 30-mg aripiprazole at steady state (Mallikaarjun et al., 2013; Raoufinia et al., 2015) . This dosing regimen has similar efficacy to oral aripiprazole in a double-blind randomized clinical trial (Fleischhacker et al., 2014; Ishigooka et al., 2015) . However, we often experience patients who require more than 2 weeks of both oral and LAI aripiprazole. (Inada & Inagaki, 2015) . The duration of oral aripiprazole use was classified into two categories (≤12 weeks or >12 weeks). The sample size was determined from the number of subjects enrolled within the study period.
Our strategy consisted of a two-step approach. First, we surveyed the prescription profile for the co-administration period and dosage of oral aripiprazole at LAI aripiprazole introduction. The clinical endpoint was the percentage of patients using oral aripiprazole for more than 2 weeks and the median of the co-administration period in the assigned patient group. In the second approach, we assessed the influence of the co-administration period of oral and LAI aripiprazole on the clinical course. Patients were assigned to one of two groups: a 2 weeks group or more than 2 weeks group of oral aripiprazole administration after the introduction of LAI aripiprazole.
The exclusion criteria included unknown patient background, less than 2 weeks co-administration with the oral agent, and those who had a history of clozapine use. We excluded patients with clozapine use because it is used for treatment-resistant patients and may not accurately reflect the outcome. The clinical endpoint was either treatment failure or the addition of another medication within 12 weeks of the follow-up period. Treatment failure was defined as psychiatric hospitalization or discontinuation of LAI aripiprazole from any cause. Psychiatric hospitalization included inpatients that required treatment at the hospital for 12 weeks after the introduction of LAI aripiprazole. Additional medication was assessed separately for AP drugs other than aripiprazole and benzodiazepines. Patients who were administered additional aripiprazole were excluded because it could be regarded as an extension of the co-administration period with an oral agent. This study was approved by the institutional review board of each hospital.
| Statistical analysis
The baseline characteristics of the patients were assessed using a Student's t test for continuous variables. Comparisons of percentage were conducted using Fisher's exact test. The association between the co-administration period with an oral agent and each endpoint was assessed using multivariate logistic regression analysis. We used propensity score adjustment for possible confounding variables for the multivariable model because patients were not randomly assigned (Joffe & Rosenbaum, 1999) . Covariates were chosen for their potential association with each endpoint of interest based on clinical knowledge. The propensity score created through a logistic regression model included 14 covariates and is shown in Table 1 . This model yielded a c statistic of 0.81, which means that the treatment assignment depended only on covariates and not directly on result variables (treatment assignment was strongly ignorable). Finally, we used a logistic regression model including propensity score as a covariate.
All statistical analyses were performed with R 3.4.0 (The R Foundation for Statistical Computing). The p values were two-sided, and those less than 0.05 were considered significant. 
| Patient characteristics
A total of 106 patients were analyzed, and 15 patients were excluded based on the above criteria ( Figure 2 ). Fifty-two patients were assigned to the 2 weeks group (males, 18; females, 34; mean age ± SD, 44.9 ± 16.1), and 54 were assigned to the more than 2 weeks group (males, 22; females, 32; mean age ± SD, 45.6 ± 14.0). Significant differences between both groups were only observed when comparing the institution (university vs. psychiatric hospital). The patient characteristics are summarized in Table 1 .
| Propensity score analysis
The association between the co-administration period and clinical course is summarized in Table 2 . In the univariate analysis, there were no significant differences between groups in treatment failure during the 12-week follow-up period (21.2% vs. 13.0%, p = 0.31).
The reasons for discontinuing LAI aripiprazole were inefficacy (N = 6) and akathisia (N = 1, 2 weeks group 
| DISCUSSION
We investigated the period of oral aripiprazole administration in conjunction with LAI aripiprazole introduction on the clinical course. The combined oral and LAI period is defined as 2 weeks on the medical package insert, but approximately 40% of the patients were administered both oral and LAI aripiprazole beyond this specified period.
The median co-administration period was 4 weeks in the more than 2 weeks group at which the serum concentration had the lowest Unknown patient background N=6.
Less than 2 weeks co-administration period N=7.
Clozapine use N=2.
concentration of LAI aripiprazole (immediately before the second administration). A pharmacokinetics study reported that the serum concentration of LAI aripiprazole gradually decreases following the initial administration and falls below 150 ng/ml after 3 weeks (Mallikaarjun et al., 2013) . A clinical dose of aripiprazole results in striatal dopamine 2 and 3 (D 2 /D 3 ) receptor occupancy exceeding 80% (Mamo et al., 2007; Yokoi et al., 2002) , which requires a concentration range of 150-210 ng/ml (Sparshatt, Taylor, Patel, & Kapur, 2009 ). Therefore, the combination of oral aripiprazole as prescribed for only 2 weeks may result in insufficient serum concentrations. A higher rate of administering additional medication in the 2 weeks group is indicative of the requirement of concomitant medicine to compensate for the reduced serum concentration of aripiprazole.
Therefore, extending the co-administration period of aripiprazole may prevent these events and the need for polypharmacy.
Although treatment failure was higher for the 2 weeks group compared with the more than 2 weeks group, there were no significant differences. One reason may be that treatment failure is a severe event. Clinical trials have reported that the discontinuation rate from any cause is approximately 25% (Ishigooka et al., 2015) , and various factors other than serum concentration are affected. Similarly, the addition of other psychotic agents made a nominal difference (only univariate analysis) between the groups, and the exacerbation of psychiatric symptoms sometimes cannot be avoided. The results from our study showed that the administration of additional benzodiazepines significantly reduced the extension of the co-administration period.
Therefore, it may be effective for preventing peripheral symptoms, such as anxiety and insomnia, caused by LAI introduction.
We expected that overdosing would cause an extension of the co-administration period of oral and LAI aripiprazole, but no discontinuation from adverse events was observed. LAI is commonly introduced after confirming efficacy and safety, a feature that highlights the unique pharmacologic profile of aripiprazole. That is, the risk of adverse events is less likely to increase in a dose-dependent manner because aripiprazole acts as a partial agonist to the dopamine D 2 receptor (Burris et al., 2002) . This event was demonstrated in a previous clinical trial in which aripiprazole was not correlated with dose or adverse events, with the exception of somnolence (Marder et al., 2003) .
Our study had several limitations. First, we adjusted for possible confounding factors using propensity score methods. However, the propensity score method is not able to only adjust for observed This study provides preliminary evidence for differences in the coadministration period of oral aripiprazole at LAI aripiprazole introduction. Our results showed that patients who received both oral and LAI aripiprazole in accordance with the medical package insert were more likely to receive additional benzodiazepines than those whose co-administration treatment period were extended. Although further prospective studies with larger sample sizes are needed, the results from this study demonstrate the efficacy of a flexible coadministration period of aripiprazole. 
